教師資料查詢 | 類別: 期刊論文 | 教師: 張玉坤 Yue-cune Chang (瀏覽個人網頁)

標題:D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
學年94
學期2
出版(發表)日期2006/02/01
作品名稱D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
作品名稱(其他語言)
著者Tsai, Guochuan E.; Yang, Pinchen; 張玉坤; Chang, Yue-cune; Chong, Mian-yoon
單位淡江大學數學學系
出版者Elsevier
著錄名稱、卷期、頁數Biological Psychiatry 59(3), pp.230-234
摘要Background

Hypofunction of the N-methyl-d-aspartate (NMDA) subtype glutamate receptor had been implicated in the pathophysiology of schizophrenia. Treatment with D-serine, glycine, endogenous full agonists of the glycine site of the NMDA receptor (NMDA-glycine site), D-cycloserine, a partial agonist, or sarcosine, a glycine transporter-1 inhibitor, improves the symptoms of schizophrenia. D-alanine is another endogenous agonist of the NMDA-glycine site that might have beneficial effects on schizophrenia.

Methods

Thirty-two schizophrenic patients enrolled in a 6-week double-blind, placebo-controlled trial of D-alanine (100 mg/kg/day), which was added to their stable antipsychotic regimens. Measures of clinical efficacy and side effects were determined every other week.

Results

Patint who received D-alanine treatment revealed significant reductions in their Clinical Global Impression Scale and Positive and Negative Syndrome Scale (PANSS) total scores. The Scale for the Assessment of Negative Symptoms and PANSS subscores of positive and cognitive symptoms were improved. D-alanine was well tolerated, and no significant side effect was noted.

Conclusions

The significant improvement with the D-alanine further supports the hypothesis of hypofunction of NMDA neurotransmission in schizophrenia and strengthens the proof of the principle that NMDA-enhancing treatment is a promising approach for the pharmacotherapy of schizophrenia.
關鍵字N-methyl-D-aspartate;glutamate;schizophrenia;treatment-resistant
語言英文
ISSN0006-3223
期刊性質國內
收錄於
產學合作
通訊作者
審稿制度
國別中華民國
公開徵稿
出版型式,電子版
相關連結
SDGs
Google+ 推薦功能,讓全世界都能看到您的推薦!